Gapping up In reaction to strong earnings/guidance: MOBL +11.7%, QTM +11.5%, ALU +10.2%, LOPE +9.9%, FLTX +9.2%, FORM +8.2%, CALX +7.5%, HOS +7.5%, TTWO +7.5%, CJES +6.3%, TASR +6.3%, RNG +5.1%, PPC +4.5%, AMAG +4.4%, ACHC +3.8%, CAVM +3.8%, V +3.5%, JDSU +3.3%, ARRS +3%, LLL +3%, FFIV +2.9%, NCIT +2.9%, CAR +2.9%, INCY +2.8%, DWA +2.7%, CRUS +2.6%, CLD +2.6%, VPRT +2.6%, ESV +2.4%, CEMP +2.2%, IQNT +2.1%, HST +2%, MET +1.8%, NEWP +1.8%, VECO +1.8%, ORN +1.8%, MA +1.7%, SLCA +1.6%, MMYT +1.6%, DRIV +1.4%, SPRT +1.4%, ALLE +1.4%, CRR +1.4%, EQIX +1.3%, LNC +1.3%, LOCK +1.2%, GBX +1.2%, MDXG +1.2%, COP +1.2%, NGD +1.2%, ARII +1.1%, ALDW +1.1%, NEO +1.1%, EPD +1.1%, QUIK +1%, .
M&A news: PDII +92% (Digirad delivers letter to PDI expressing willingness to acquire the company at a premium to current market price in combination of cash and stock )
Other news: LAKE +42.5% (provides update on business activity relating to Ebola crisis; The co has been experiencing significant interest globally for its ChemMAX and MicroMAX protective suit lines), APT +16.6% (following LAKE Ebola update), IBIO +14.7% (in symp with LAKE announcement), LOPE +9.9% (Board formed an independent committee to explore options aimed at enhancing stockholder value), FORM +8.2% (announced Mike Slessor will become CEO starting fiscal 2015), HOS +7.5% (Board authorized $150 mln share repurchase program), NVAX +7.2% (U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M), NAVB +5.1% (announces scientific presentations of results from Lymphoseek studies at the European Association of Nuclear Medicine), BBSI +5% (following 50%+ decline yesterday on earnings), LVLT +3.8% (Level 3 to join S&P 500 11/4 ), CBSO +3.2% (co's Board has approved a special dividend on the company's common stock of ~$547.7 million, or $4.56 per share), TBIO +2.9% (co and University of Melbourne collaborate to further validate ability of multiplexed ICE COLD-PCRTM)
Analyst comments: NFX +0.8% (upgraded to Buy from Hold at Societe Generale)